First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone
Status:
Terminated
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics,
pharmacodynamics and early efficacy signs of M3258 as a single agent and co-administered with
dexamethasone in participants with Relapsed Refractory Multiple Myeloma (RRMM).